Clavulox L.C. is formulated for the treatment of mastitis in lactating cows. It has a notably broad spectrum of bactericidal activity against the bacteria commonly isolated from the bovine udder. Cases responding successfully to treatment include infections with the following major pathogens: Staphylococci spp. (including ß-lactamase producing strains); Streptococci spp. (including S. agalactiae, S. dysgalactiae and S. uberis); Escherichia coli (including ß-lactamase producing strains).
Resistance to many antibiotics is caused by ß-lactamase enzymes that destroy the antibiotic before it can act on the bacteria. The clavulanate in the product counteracts this defence mechanism by inactivating the ß-lactamases, thus rendering the bacteria sensitive to the rapid bactericidal effect of amoxycillin at concentrations readily attainable in the udder. Prednisolone has an anti-inflammatory action that helps to reduce the potentially destructive swelling and inflammation associated with mastitis, without affecting the white cell response to infection.
In-vitro, the product is active against a wide range of clinically important bacteria, including the following organisms that are commonly associated with bovine mastitis. Staphylococci spp. (including ß-lactamase producing strains), Streptococci spp. (including S. agalactiae, S. dysgalactiae and S. uberis), Actinomyces (Corynebacterium) (including A. pyogenes), Escherichia coli (including ß-lactamase producing strains). In addition, it is active in vitro against many of the less common udder pathogens, including: Bacillus cereus, Bacteroides (including ß-lactamase producing strains), Campylobacter spp. Klebsiellae and Pasteurellae. Clinically, the product has been shown to be an effective routine treatment for mastitis in lactating cows.
Dairy Cattle